Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2013Journal of Clinical OncologyOpen Access

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJyoti D. PatelNorthwestern UniversityMSMark A. SocinskiFlorida Hospital Cancer InstituteEGEdward B. GaronUniversity of California, Los Angeles

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Patel et al. (2013) studied this question.

synapsesocial.com/papers/6985ef813b00292770426f2dhttps://doi.org/10.1200/jco.2012.47.9626
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The National Comprehensive Cancer Network1998 · 16,882 citations
  2. 2Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer2002 · 368 citations
  3. 3Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma2002 · 149 citations
  4. 4Characterizing the cancer genome in lung adenocarcinoma2007 · 1,126 citations
  5. 5Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer2001 · 918 citations